Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONCY Oncolytics Biotech Inc

Post-Mkt 10-06 16:08:15 EDT

0.5980

+0.0011

+0.18%

盘后0.5980

+0.00000.00%

16:04 EDT

High0.6050	Low0.5757	Vol855.11K
Open0.6000	D1 Closing0.5969	Amplitude4.91%
Mkt Cap76.25M	Tradable Cap73.54M	Total Shares127.51M
T/O509.71K	T/O Rate0.70%	Tradable Shares122.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONCY","market":"US","secType":"STK","nameCN":"Oncolytics Biotech Inc","latestPrice":0.598,"timestamp":1791316800000,"preClose":0.5969,"halted":0,"volume":855109,"hourTrading":{"tag":"盘后","latestPrice":0.598,"preClose":0.598,"latestTime":"16:04 EDT","volume":5,"amount":2.9899999999999998,"timestamp":1791317043541,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0018428547495392693,"floatShares":122973676,"shares":127510505,"eps":-0.3215,"marketStatus":"Post-Mkt","change":0.0011,"latestTime":"10-06 16:08:15 EDT","open":0.6,"high":0.605,"low":0.5757,"amount":509711,"amplitude":0.049087,"askPrice":0.6504,"askSize":200,"bidPrice":0.59,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-0.3215,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791331200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1002254400000,"exchange":"NASDAQ","adjPreClose":0.5969,"preHourTrading":{"tag":"盘前","latestPrice":0.6008,"preClose":0.5969,"latestTime":"09:28 EDT","volume":1019,"amount":613.7849695,"timestamp":1791293284244,"change":0.0039,"changeRate":0.006534,"amplitude":0.058636},"postHourTrading":{"tag":"盘后","latestPrice":0.598,"preClose":0.598,"latestTime":"16:04 EDT","volume":5,"amount":2.9899999999999998,"timestamp":1791317043541,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.873273},"requestUrl":"/m/hq/s/ONCY","defaultTab":"news","newsList":[{"id":"2671210185","title":"Oncolytics announces publication of data on pelareorep in liver cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2671210185","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671210185?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:45","pubTimestamp":1790689517,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) Biotech announced data published in the Proceedings of the National Academy of Sciences show pelareorep’s ability to change an im...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-announces-publication-of-data-on-pelareorep-in-liver-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-announces-publication-of-data-on-pelareorep-in-liver-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XBI","ONCY","BK4588","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671217904","title":"Oncolytics Biotech Says Study Shows Pelareorep Triggers Immune Activation in Liver Cancer, Boosting Immunotherapy Sensitivity","url":"https://stock-news.laohu8.com/highlight/detail?id=2671217904","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671217904?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:30","pubTimestamp":1790688651,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech says study shows pelareorep triggers immune activation in liver cancer, boosting immunotherapy sensitivityOncolytics Biotech flagged a peer-reviewed publication dated Sept. 28, 2026","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL9sn2Wk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","SG9999014039.USD","IE00BQXX3D17.EUR","SG9999014021.USD","ONCY","IE00BQXX3F31.USD","BK4585","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","BK4112","BK4139","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BQXX3C00.GBP","SG9999014013.SGD","BK4588","LU0314104364.USD","BCDF","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670258185","title":"Oncolytics reports accelerating enrollment in REO 033 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2670258185","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670258185?lang=en_us&edition=fundamental","pubTime":"2026-09-28 21:35","pubTimestamp":1790602542,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) Biotech announced continued clinical and operational progress in REO 033, its randomized study evaluating pelareorep in second-li...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-reports-accelerating-enrollment-in-reo-033-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-reports-accelerating-enrollment-in-reo-033-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY","BK4581","XBI","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670625833","title":"Oncolytics Biotech - Expects Interim Part a Clinical Update by Year-End 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2670625833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670625833?lang=en_us&edition=fundamental","pubTime":"2026-09-28 21:30","pubTimestamp":1790602200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nTUACBFVNJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670258332","title":"Oncolytics Biotech® Reports Accelerating Enrollment in Randomized Reo 033 Ras-Mutant, Mss Colorectal Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2670258332","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670258332?lang=en_us&edition=fundamental","pubTime":"2026-09-28 21:30","pubTimestamp":1790602200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nTUACBFVNJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670740486","title":"Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670740486","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670740486?lang=en_us&edition=fundamental","pubTime":"2026-09-28 05:30","pubTimestamp":1790544629,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE). Oncolyti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oncolytics-biotech-oncy-and-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oncolytics-biotech-oncy-and-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4588","SYRE","ONCY","BK4585","XBI","BK4137","BK4581","XLV","HCSG","LFSC","LABU","LU0029874061.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669670261","title":"Oncolytics Biotech (ONCY) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2669670261","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669670261?lang=en_us&edition=fundamental","pubTime":"2026-09-22 01:56","pubTimestamp":1790013389,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Oncolytics Biotech, with a price target of $5.00. Truc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oncolytics-biotech-oncy-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oncolytics-biotech-oncy-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666593981","title":"Oncolytics Reports Positive Preclinical Data Combining Pelareorep with Pan-RAS Inhibitor in Colorectal Cancer Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2666593981","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666593981?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:15","pubTimestamp":1789042529,"startTime":"0","endTime":"0","summary":"Oncolytics reports positive preclinical data combining pelareorep with pan-RAS inhibitor in colorectal cancer modelOncolytics Biotech announced positive preclinical results for pelareorep combined wit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL4btktp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","SG9999014039.USD","IE00BQXX3D17.EUR","SG9999014021.USD","ONCY","IE00BQXX3F31.USD","BK4585","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","BK4112","BK4139","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BQXX3C00.GBP","SG9999014013.SGD","BK4588","LU0314104364.USD","BCDF","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666936155","title":"Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-Ras Inhibitor in Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2666936155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666936155?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:15","pubTimestamp":1789042500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUAYFKFL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660414954","title":"Oncolytics Biotech Inc. : H.c. Wainwright Cuts Target Price to $5 from $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2660414954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660414954?lang=en_us&edition=fundamental","pubTime":"2026-08-19 18:01","pubTimestamp":1787133717,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nAZN4TF7FJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660438984","title":"U.S. Research Roundup-Cogent Communications, Dollar Tree, Home Depot","url":"https://stock-news.laohu8.com/highlight/detail?id=2660438984","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660438984?lang=en_us&edition=fundamental","pubTime":"2026-08-19 15:50","pubTimestamp":1787125815,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Cogent Communications, Dollar Tree, Home DepotAug 19 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL4N44G0KE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGW","HOMZ","ARMK","HONA","GPN","MD","TBLU","TRUM","ECL","ONCY","HD","MCK","DLTR","MADE","NUKX","SPSC","KEYS","VEGI","DE","AMLX","PKB","SEPN","CCOI","CAH","BAND","RSPS","SJM","IDEF","SHLD","BZZ","WDGF","EVX","BPAY","FOWF","ELF","TDS","RTH","D","KROP","NOC","ZAP","AD","AGCO","COR","HSIC","HWAY","MRCY","FTAG","FSPC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660604674","title":"Oncolytics aligns with FDA on path for REO 033 expansion study","url":"https://stock-news.laohu8.com/highlight/detail?id=2660604674","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660604674?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:16","pubTimestamp":1787058974,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) announced that it has received written feedback from the FDA regarding the design of a potential pivotal Part B expansion of REO ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-aligns-with-fda-on-path-for-reo-033-expansion-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-aligns-with-fda-on-path-for-reo-033-expansion-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY","BK4588","BK4585","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660677754","title":"Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line Ras-Mutant Mss Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660677754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660677754?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:02","pubTimestamp":1787058136,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F104:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660677204","title":"Oncolytics Biotech - Receives FDA Feedback on Pivotal Part B Expansion of Reo 033","url":"https://stock-news.laohu8.com/highlight/detail?id=2660677204","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660677204?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:02","pubTimestamp":1787058136,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F104:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660146703","title":"Oncolytics Says FDA Aligns on Pivotal Expansion Path for REO 033 Colorectal Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660146703","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660146703?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:01","pubTimestamp":1787058082,"startTime":"0","endTime":"0","summary":"Oncolytics says FDA aligns on pivotal expansion path for REO 033 colorectal cancer trialOncolytics received FDA written feedback supporting a registrational path to expand its REO 033 colorectal cance","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL5Jc8mD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BQXX3D17.EUR","SG9999014021.USD","BK4139","SG9999014039.USD","BCDF","IE00BKPKM429.USD","IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","NDAQ","BK4112","ONCY","BK4585","SG9999014013.SGD","BK4588","LU0314104364.USD","LU2210150020.SGD","LU2095319765.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900262","title":"Oncolytics Net Loss Widens to $9.44 Million in Q2 2026; R&D Expenses More than Doubled to $4.26 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900262","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900262?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:22","pubTimestamp":1786566168,"startTime":"0","endTime":"0","summary":"Oncolytics net loss widens to $9.44 million in Q2 2026; R&D expenses more than doubled to $4.26 millionOncolytics Biotech posted a Q2 net loss of USD 9.44 million, widening from USD 5.28 million a yea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLb4ZDkf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654037844","title":"Oncolytics Biotech Gets NASDAQ Notice for Failing $1 Minimum Bid Price Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2654037844","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654037844?lang=en_us&edition=fundamental","pubTime":"2026-07-25 04:43","pubTimestamp":1784925833,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech gets Nasdaq notice for failing $1 minimum bid price ruleOncolytics Biotech received a Nasdaq notice for failing the $1 minimum bid price rule after ONCY closed below $1 for 30 strai","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL3dh53V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652170216","title":"Oncolytics Biotech Announces Press Release Available","url":"https://stock-news.laohu8.com/highlight/detail?id=2652170216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652170216?lang=en_us&edition=fundamental","pubTime":"2026-07-20 21:23","pubTimestamp":1784553798,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech announces press release availableOncolytics Biotech disclosed FDA Fast Track designation for pelareorep with a checkpoint inhibitor in second-line or later anal cancer.Designation t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL5gxmKj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652216395","title":"Oncolytics Biotech Wins FDA Fast Track Status for Pelareorep in Second-line Anal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2652216395","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652216395?lang=en_us&edition=fundamental","pubTime":"2026-07-20 21:08","pubTimestamp":1784552882,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech wins FDA Fast Track status for pelareorep in second-line anal cancerOncolytics Biotech won FDA Fast Track designation for pelareorep with a checkpoint inhibitor in second-line or la","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL3bhsn8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","ONCY","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","BK4585","BCDF","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4139","LU2210150020.SGD","IE00BN0W2T93.GBP","BK4112","LU0314104364.USD","IE00BGHQF748.EUR","BK4588","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652215793","title":"Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-line and Later Anal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2652215793","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652215793?lang=en_us&edition=fundamental","pubTime":"2026-07-20 21:00","pubTimestamp":1784552403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nTUAMQ1JK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oncolyticsbiotech.com","stockEarnings":[{"period":"1week","weight":-0.0997},{"period":"1month","weight":-0.2921},{"period":"3month","weight":-0.3025},{"period":"6month","weight":-0.3411},{"period":"1year","weight":-0.5675},{"period":"ytd","weight":-0.317}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.006},{"period":"3month","weight":0.0363},{"period":"6month","weight":0.1462},{"period":"1year","weight":0.1578},{"period":"ytd","weight":0.1362}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.001975},{"month":2,"riseRate":0.25,"avgChangeRate":-0.025046},{"month":3,"riseRate":0.125,"avgChangeRate":-0.123611},{"month":4,"riseRate":0.75,"avgChangeRate":0.024604},{"month":5,"riseRate":0.375,"avgChangeRate":0.014597},{"month":6,"riseRate":0.25,"avgChangeRate":0.155922},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.014421},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.069615},{"month":9,"riseRate":0.111111,"avgChangeRate":-0.044849},{"month":10,"riseRate":0.444444,"avgChangeRate":0.1166},{"month":11,"riseRate":0.25,"avgChangeRate":0.020161},{"month":12,"riseRate":0.125,"avgChangeRate":0.270533}],"exchange":"NASDAQ","name":"Oncolytics Biotech Inc","nameEN":"Oncolytics Biotech Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oncolytics Biotech Inc,ONCY,Oncolytics Biotech Inc股票,Oncolytics Biotech Inc股票老虎,Oncolytics Biotech Inc股票老虎国际,Oncolytics Biotech Inc行情,Oncolytics Biotech Inc股票行情,Oncolytics Biotech Inc股价,Oncolytics Biotech Inc股市,Oncolytics Biotech Inc股票价格,Oncolytics Biotech Inc股票交易,Oncolytics Biotech Inc股票购买,Oncolytics Biotech Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}